Currently out of the existing stock ratings of Ashwani Verma, 131 are a BUY (72.38%), 44 are a HOLD (24.31%), 6 are a SELL (3.31%).
Analyst Ashwani Verma, currently employed at UBS, has had 61.68% of price targets met with an average potential upside of 27.05%, reached in 168 days on average.
Ashwani Verma has documented 362 price targets and ratings displayed on 30 stocks. The coverage is on Healthcare, Technology sectors.
Most recent stock forecast was given on AXSM, Axsome Therapeutics at 02-Nov-2026.
Analyst best performing recommendations are on CRNX (CRINETICS PHARMACEUTICALS).
The best stock recommendation documented was for CRNX (CRINETICS PHARMACEUTICALS) on 7/2/2026. The price target of $55 was fulfilled within 5 days with a profit of $12.77 (30.24%), with a performance score of 60.48.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 02-Apr-2025
$132
$132
1 years 7 months 17 days ago
(02-Apr-2025)
26/28 (92.86%)
$0.13 (0.10%)
512
Hold Since 28-Feb-2025
$132
$132
1 years 8 months 22 days ago
(28-Feb-2025)
12/14 (85.71%)
$3.8 (2.96%)
738
Buy Since 10-Dec-2020
$132
$140
1 years 8 months 26 days ago
(24-Feb-2025)
14/16 (87.5%)
$3.43 (2.67%)
274
Hold Since 21-Feb-2025
$100
1 years 8 months 29 days ago
(21-Feb-2025)
24/25 (96%)
$-27.19 (-21.38%)
152
Hold Since 08-Aug-2024
$132
$87
1 years 9 months 14 days ago
(05-Feb-2025)
7/8 (87.5%)
$4.97 (3.91%)
209
Which stock is Ashwani Verma most bullish on?
Which stock is Ashwani Verma most reserved on?
What Year was the first public recommendation made by Ashwani Verma?